{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:33:01Z","timestamp":1794580381967,"version":"4.9.1"},"reference-count":126,"publisher":"Informa UK Limited","issue":"12","funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,12,2]]},"DOI":"10.1080\/14737140.2021.1991316","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T01:26:17Z","timestamp":1634174777000},"page":"1385-1398","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":113,"title":["Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy"],"prefix":"10.1080","volume":"21","author":[{"given":"Muhammad","family":"Sohail","sequence":"first","affiliation":[{"name":"School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University) Ministry of Education, Yantai University, Yantai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University) Ministry of Education, Yantai University, Yantai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University) Ministry of Education, Yantai University, Yantai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Gu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University) Ministry of Education, Yantai University, Yantai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-4784","authenticated-orcid":false,"given":"Hui","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University) Ministry of Education, Yantai University, Yantai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03614-x"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.12.005"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-020-3124-y"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2017.1380655"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1002\/bit.260110607"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-010-2675-3"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7582730"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/echo.13871"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1021\/js970436l"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.03.023"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112843"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172818"},{"key":"cit0014","first-page":"53","volume":"374","author":"Smith T","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b09713"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700486"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700175"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15305"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/srep08400"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/aac7dd"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2020.1821676"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202862"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-418-0_7"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2921"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19247-8"},{"issue":"4","key":"cit0028","first-page":"10","volume":"25","author":"Myers C","year":"1998","journal-title":"Semin Oncol"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1042\/bj20020752"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.315812"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111333"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.11.016"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.polymer.2013.07.044"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1007\/s10853-016-0183-2"},{"issue":"3","key":"cit0035","first-page":"140","volume":"31","author":"Rusetskaya NV","year":"2009","journal-title":"Exp Oncol"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2013.04.006"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2014.12.001"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2007.12.002"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(02)00016-0"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(01)00220-6"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2007.08.016"},{"key":"cit0042","first-page":"1977","volume":"6","author":"Yousefpour P","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5b00116"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1416"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9961-7"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2017.06.008"},{"key":"cit0047","unstructured":"Lancaster JM Micro-RNA profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy. Google Patents. 2012."},{"key":"cit0048","unstructured":"Salamone SJ, Courtney JB, He S Doxorubicin immunoassay. Google Patents. 2011."},{"key":"cit0049","unstructured":"Filippini S, Lomovskaya N, Fonstein L, et al. Process for preparing doxorubicin. Google Patents. 2001."},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.683"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.07.011"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1186\/s40349-017-0104-0"},{"key":"cit0053","unstructured":"Celsion. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) i n Treatment of Hepatocellular Carcinoma (HCC). 2014. [cited 2019 July 17] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00617981"},{"key":"cit0054","unstructured":"Celsion. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). [cited 2019 June 17]. Available from: https:\/\/Clinicaltrials.Gov\/Ct2\/Show\/Study\/NCT021126562014"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2013.0202.022"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21662"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2385-z"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.10072"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70476-X"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou265.21"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000293"},{"key":"cit0063","unstructured":"Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag\u00ae [Internet]. 2017. [cited July 17]. Available from: https:\/\/www.onxeo.com\/onxeo-host-conference-call-today-comment-main-findings-relive-phase-iii-study-livatag\/"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.4195"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602204"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.06.005"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.987"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.08.003"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.2217\/fon.11.73"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.09.009"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802677874"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.12.1739"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2009.05.004"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh393"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-suppl_2-17"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082331"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2011.12.002"},{"key":"cit0083","unstructured":"Dalesio O. Clinical and pharmacological study with 2B3-101 in patients with breast cancer and leptomeningeal metastases. Clinicaltrials.Gov., editor. [cited July 17]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT018187132013."},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1007\/BF00877245"},{"key":"cit0085","unstructured":"Onxeo. Orphan oncology products: produits orphelins en oncologie. [cited July 17]. Available from: http:\/\/www.onxeo.com\/en\/nos-produits\/orphelins-oncologie\/#tabs-1-32019"},{"key":"cit0086","unstructured":"Onxeo. Livatag\u00ae (Doxorubicin TransdrugTM) follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients. [cited July 17]. Available from: http:\/\/www.onxeo.com\/wpcontent\/2011"},{"key":"cit0087","unstructured":"Onxeo. Onxeo announces top-line results from relive phase iii study of livatag\u00ae in advanced hepatocellular carcinoma. [cited July 17]. Available from: https:\/\/www.onxeo.com\/onxeo-announces-top-line-results-relive-phase-iii-study-livatag-advanced-hepatocellular-carcinoma\/2017."},{"key":"cit0088","unstructured":"Reynolds JG, Olivier KJ, Hendriks BS, et al. Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents. Google Patents. 2016."},{"issue":"4","key":"cit0089","first-page":"1172","volume":"8","author":"Park JW","year":"2002","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(01)00315-7"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.13.8"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1668"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1191\/096032701682693017"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666201005111722"},{"key":"cit0095","unstructured":"Ofner III CM, Cammarata C, Rhodes B, et al. High molecular weight biodegradable gelatin-doxorubicin conjugate. Google Patents. 2019."},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.7150\/jca.50575"},{"key":"cit0097","unstructured":"Egorov M, Goujon J-Y, Le Bot R, et al. Hydrosoluble hydroxybisphosphonic derivatives of doxorubicin. Google Patents. 2019."},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040480"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922072117"},{"key":"cit0100","unstructured":"Liu C, Liu Y Legumain activated doxorubicin derivative as well as preparation method and application thereof. Google Patents. 2018."},{"key":"cit0101","unstructured":"Borb\u00e9ly J, Csik\u00f3s Z, Koncz G, et al. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it. Google Patents. 2015."},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2008.08.017"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1002\/med.21461"},{"key":"cit0104","unstructured":"Garland WA, Frenzel BD Doxorubicin adjuvants to reduce toxicity and methods for using the same. Google Patents. 2015."},{"key":"cit0105","unstructured":"Garland WA, Frenzel BD Doxorubicin adjuvants to reduce toxicity and methods for using the same. Google Patents. 2012."},{"key":"cit0106","unstructured":"Demeule M, Che C, Gabathuler R, et al. Etoposide and doxorubicin conjugates for drug delivery. Google Patents. 2014."},{"key":"cit0107","unstructured":"Demeule M, Che C, Gabathuler R, et al. Etoposide and doxorubicin conjugates for drug delivery. Google Patents. 2016."},{"key":"cit0108","unstructured":"Fiume L, Di Stefano G, Lanza M Process for the preparation of doxorubicin conjugates with lactosaminated human albumin. Google Patents. 2009."},{"key":"cit0109","unstructured":"Ruangwattanasuk O Doxorubicin derivatives and uses thereof. Google Patents. 2020."},{"key":"cit0110","unstructured":"Tomas Etrych K, Petr CPKU, Prague TM, Holesov, Blanka Rihova, Prague. Grafted macromolecular conugates of doxorubcn with anticanceractivity and method of ther preparation. Google Patents. 2013."},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.8b17399"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-019-07231-2"},{"key":"cit0113","unstructured":"Raucher D, Bidwell III G, Priebe W, et al. Thermally-targeted delivery of medicaments including doxorubicin. Google Patents. 2012."},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2017.03.024"},{"key":"cit0115","unstructured":"Klinski E, Patel K, Pietrzynski G, et al. Doxorubicin formulations for anti-cancer use. Google Patents. 2012."},{"key":"cit0116","unstructured":"Johdo O, Nakao T, Yoshioka T Crystallization of doxorubicin hydrochloride. Google Patents. 2003."},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2019.01.075"},{"key":"cit0118","unstructured":"Rashida A, Karmali B Method of reducing cardiaclevels of doxorubcn when given as orotate salt. Google Patents. 2012."},{"issue":"1","key":"cit0119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6169-0","volume":"20","author":"Martins JMA","year":"2020","journal-title":"BMC Cancer"},{"key":"cit0120","unstructured":"Kratz F Protein-binding doxorubicin peptide derivatives. Google Patents. 2010."},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16723"},{"key":"cit0122","unstructured":"Bissery M-C. Method of treating cancer with docetaxel and doxorubicin. Google Patents. 2011."},{"key":"cit0123","unstructured":"Rozencweig M, Goldfarb RH, Forenza S Non-pegylated liposomal doxorubicin triple combination therapy. Google Patents. 2011."},{"key":"cit0124","unstructured":"Gabizon A, Ohana P, Shmeeda H Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C. Google Patents. 2020."},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S46900"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.04.025"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1991316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T01:48:42Z","timestamp":1637027322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1991316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":126,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,2]]}},"alternative-id":["10.1080\/14737140.2021.1991316"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1991316","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}